Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276579 | 0.80 | CA2 (1.00) | CA2CA1CA12CA7CA14 | |
| SCHEMBL4603698 | 0.76 | CA2 (0.70) | CA2CA1CA12CA7CA14 | |
| SCHEMBL4243562 | 0.73 | CA2 (1.00) | CA2CA1CA12 | |
| SCHEMBL29425310 | 0.73 | CA2 (1.00) | CA2CA1CA12 | |
| SCHEMBL14140910 | 0.71 | CA2 (0.70) | CA2CA1KIF11ENPP1PTGS2 | |
| SCHEMBL2094565 | 0.71 | IDO1 (0.36) | CA2 | |
| SCHEMBL30788041 | 0.69 | MPL (0.41) | — | |
| SCHEMBL29160952 | 0.69 | MPL (0.41) | — | |
| SCHEMBL19119067 | 0.67 | CA2 (0.59) | CA2CA1CA12CA7CA14 | |
| SCHEMBL17207797 | 0.66 | SLC9A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794143-B1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | claimed |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | SMITH-SWINTOSKY VIRGINIA L | 2007-12-20 | — | — | US | claimed |
| WO-2007095609-A2 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-23 | — | — | WO | claimed |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| US-20070191449-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-20070191460-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| US-20070191461-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| US-20070191450-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder | SMITH-SWINTOSKY VIRGINIA L | 2007-08-16 | — | — | US | claimed |
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | ABDEL-MAGID AHMED F | 2006-12-07 | — | — | US | claimed |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACAEUTICA N.V. (BE) | 2006-03-02 | — | — | US | claimed |
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-09 | — | — | US | disclosed |
| EP-1794143-B8 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1794143-B1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1794143-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | ABDEL-MAGID AHMED F | 2006-12-07 | — | — | US | disclosed |
| WO-2006023861-A1 | NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | JANSSEN PHARMACAEUTICA N.V. (BE) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276528-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRA5, SULT2A1, SYNGR2 | CA2 884/4885CA1 584/4885KIF11 3526/4885 |
| US-20070191461-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SULT2A1, CNR2, FAAH2 | CA2 764/4885CA1 2640/4885KIF11 3571/4885 |
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | STS, SULT2A1, SULT1A1 | CA2 1316/4885CA1 449/4885KIF11 3910/4885 |
| US-20070191449-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression | TPH2, SULT2A1, SDHA | CA2 3373/4885CA1 3750/4885KIF11 3874/4885 |
| US-20070191451-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | NLN, CTSA, SMN1; SMN2 | CA2 3775/4885CA1 1975/4885KIF11 3691/4885 |
| US-20060047001-A1 | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | GABRE, GABRB2, GABRA2 | CA2 1986/4885CA1 1270/4885KIF11 3639/4885 |
| US-20070191460-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis | SULT2A1, GABRB2, GABRB1 | CA2 1034/4885CA1 579/4885KIF11 3778/4885 |
| US-20070191459-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels | LIPC, GPR119, APOB | CA2 2846/4885CA1 4810/4885KIF11 4549/4885 |
| US-20070293476-A1 | CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | GABBR1, SYNGR2, GABBR2 | CA2 1100/4885CA1 776/4885KIF11 3685/4885 |
| US-20070191450-A1 | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder | GABBR1, GABBR2, GABRB2 | CA2 3217/4885CA1 3112/4885KIF11 3574/4885 |
| US-20070191452-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, SULT2A1, OPRK1 | CA2 1153/4885CA1 2809/4885KIF11 3677/4885 |
| US-20070191453-A1 | USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | CA2 4722/4885CA1 4715/4885KIF11 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.